2,371 followers
Conclusion: KRAS mutations and the protein expression of EGFR and PKC-alpha should be evaluated as predictive biomarkers in patients with LGSC treated with MEKi. https://t.co/dx99DiLZyO
Conclusion: KRAS mutations and the protein expression of EGFR and PKC-alpha should be evaluated as predictive biomarkers in patients with LGSC treated with MEKi. https://t.co/dx99DiLZyO
We enjoyed reading about how our Partek Flow customers discovered oncogenic biomarker mutations. One day, this could lead to better ovarian cancer treatment. https://t.co/cOQiuLHbx2 #ovariancancer #genomics #BioInformatics https://t.co/U4GrWFcuLi